Role of disturbed fatty acids metabolism in the pathophysiology of diabetic erectile dysfunction

Lipids Health Dis. 2017 Dec 12;16(1):241. doi: 10.1186/s12944-017-0637-9.

Abstract

Background: Vasculogenic erectile dysfunction (VED) is considered as a common complication among people with type 2 diabetes (T2D). We tested whether changes in fatty acid (FAs) classes measured in erythrocytes are associated with increased risk of diabetic VED along with related risk factors.

Methods: We assessed erythrocyte FAs composition, lipid peroxidation parameters and inflammatory cytokines among 72 T2D men with VED, 78 T2D men without VED and 88 healthy volunteers with similar age. Biochemical, hepatic, lipid and hormonal profiles were measured.

Results: T2D people with VED had significant decrease in the indexes of Δ6-desaturase and elongase activities compared to the other studied groups. The same group of participants displayed lower erythrocytes levels of dihomo-γ-linolenic acid (C20:3n-6) (P < .001), precursor of the messenger molecule PGE1 mainly involved in promoting erection. Moreover, absolute SFAs concentration and HOMA IR levels were higher in T2D people with VED when compared to controls and associated with impaired NO concentration (1.43 vs 3.30 ng/L, P < .001). Our results showed that IL-6 and TNF-α were significantly increased and positively correlated with MDA levels only in T2D people with VED (r = 0.884, P = .016 and r = 0.753, P = .035; respectively) suggesting a decrease in the relative availability of vasodilator mediators and an activation of vasoconstrictors release.

Conclusion: Our findings show that the deranged FAs metabolism represents a potential marker of VED in progress, or at least an indicator of increased risk within men with T2D.

Keywords: Diabetic erectile dysfunction; Fatty acids; Inflammation; Insulin resistance; Type 2 diabetes.

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / blood*
  • Acetyltransferases / blood*
  • Acetyltransferases / genetics
  • Aged
  • Alprostadil / blood
  • Biomarkers / blood
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Erythrocytes / metabolism*
  • Erythrocytes / pathology
  • Fatty Acid Elongases
  • Gene Expression
  • Humans
  • Impotence, Vasculogenic / complications
  • Impotence, Vasculogenic / genetics
  • Impotence, Vasculogenic / metabolism*
  • Impotence, Vasculogenic / physiopathology
  • Interleukin-6 / blood
  • Interleukin-6 / genetics
  • Linoleoyl-CoA Desaturase / blood*
  • Linoleoyl-CoA Desaturase / genetics
  • Lipid Metabolism
  • Lipid Peroxidation
  • Male
  • Middle Aged
  • Nitric Oxide / blood
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Biomarkers
  • IL6 protein, human
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • Linoleoyl-CoA Desaturase
  • Acetyltransferases
  • Fatty Acid Elongases
  • Alprostadil
  • 8,11,14-Eicosatrienoic Acid